Clostridium difficile: progress and challenges

被引：73

作者：

Bartlett, John G. ^{[1
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA

来源：

ANTIMICROBIAL THERAPEUTICS REVIEWS | 2010年 / 1213卷

关键词：

Clostridium difficile; C; difficile; antibiotic-associated colitis; pseudomenbraneous colitis; epidemiology; fluoroquinolones; oral vancomycin; new guidelines; tests; and treatments; RANDOMIZED CONTROLLED-TRIAL; LINKED-IMMUNOSORBENT-ASSAY; TIME PCR ASSAY; PSEUDOMEMBRANOUS COLITIS; EMERGENCY COLECTOMY; TOXIN PRODUCTION; FUSIDIC ACID; VANCOMYCIN; METRONIDAZOLE; INFECTION;

D O I：

10.1111/j.1749-6632.2010.05863.x

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

There is a surge of new interest in C. difficile infection (CDI) reflecting substantial increases in cases and fatalities. The new challenges by this now old pathogen have brought renewed interest in all facets of the disease. Particularly important are the role of fluoroquinolones as inducing agents, the new polymerase chain reaction test to detect toxigenic strains in stools, the important role of the NAP-1 strain, recent evidence favoring oral vancomycin over metronidazole in seriously ill patients, and new guidelines for management.

引用

页码：62 / 69

页数：8

共 78 条

[1] Recurrent Clostridium difficile colitis:: Case series involving 18 patients treated with donor stool administered via a nasogastric tube [J].

Aas, J ;

Gessert, CE ;

Bakken, JS .

CLINICAL INFECTIOUS DISEASES, 2003, 36 (05) :580-585

[2]

Abougergi Marwan S, 2010, J Hosp Med, V5, pE1, DOI 10.1002/jhm.542

[3] ANTIMICROBIAL AGENTS AND CLOSTRIDIUM-DIFFICILE IN ACUTE ENTERIC DISEASE - EPIDEMIOLOGICAL DATA FROM SWEDEN, 1980-1982 [J].

ARONSSON, B ;

MOLLBY, R ;

NORD, CE .

JOURNAL OF INFECTIOUS DISEASES, 1985, 151 (03) :476-481

[4] Emergence of reduced susceptibility to metronidazole in Clostridium difficile [J].

Baines, Simon D. ;

O'Connor, Rachael ;

Freeman, Jane ;

Fawley, Warren N. ;

Harmanus, Celine ;

Mastrantonio, Paola ;

Kuijper, Ed J. ;

Wilcox, Mark H. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 62 (05) :1046-1052

[5] Fecal bacteriotherapy for recurrent Clostridium difficile infection [J].

Bakken, Johan S. .

ANAEROBE, 2009, 15 (06) :285-289

[6] The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection [J].

Bartlett, John G. .

CLINICAL INFECTIOUS DISEASES, 2008, 46 (10) :1489-1492

[7] Narrative review: The new epidemic of clostridium difficile-associated enteric disease [J].

Bartlett, John G. .

ANNALS OF INTERNAL MEDICINE, 2006, 145 (10) :758-764

[8] New antimicrobial agents for patients with Clostridium difficile infections [J].

Bartlett J.G. .

Current Infectious Disease Reports, 2009, 11 (1) :21-28

[9]

Bhangu A, 2010, J INVEST MED, V58, P621, DOI 10.231/JIM.0b013e3181d5d9e0

[10] FECAL METRONIDAZOLE CONCENTRATIONS DURING ORAL AND INTRAVENOUS THERAPY FOR ANTIBIOTIC ASSOCIATED COLITIS DUE TO CLOSTRIDIUM-DIFFICILE [J].

BOLTON, RP ;

CULSHAW, MA .

GUT, 1986, 27 (10) :1169-1172

← 1 2 3 4 5 6 7 8 →